In a review of the pricey new prostate cancer treatments hitting the market, Reuters directed its spotlight to Medivation's MDV3100, noting its closely watched status as the biotech readies a crucial interim analysis later this year. For Medivation, which has been bitterly disappointed in its studies of the experimental Alzheimer's treatment Dimebon, the cancer data will present a major catalyst on its stock price. "MDV3100 is certainly promising...but we haven't seen the data yet," says Dr. Elizabeth Plimack, an oncologist at Philadelphia's Fox Chase Cancer Center. Report